Please assess the completion status of the following clinical trial:

Trial Title: A Study of Venetoclax in Combination With Obinutuzumab in Participants With Chronic Lymphocytic Leukemia

Study Design Characteristics:
- Allocation: NON_RANDOMIZED
- Intervention Model: SEQUENTIAL
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: NONE
- Phase: PHASE1
- Number of Arms: 6.0

Eligibility Criteria:
Inclusion Criteria:~* Diagnosis of relapsing/refractory or previously untreated chronic lymphocytic leukemia~* Eastern Cooperative Oncology Group (ECOG) performance score of less than or equal to (\</=) 1~* Adequate bone marrow function~* Adequate coagulation, renal and hepatic function~* For all participants, agreement to remain abstinent or use contraceptive methods that result in a failure rate of less than (\<) 1% per year during the treatment period and for at least 90 days (30 days for women) after the last dose of venetoclax or 18 months after the last dose of obinutuzumab, whichever is longer~Exclusion Criteria:~* Participants who have undergone allogenic stem cell transplant are ineligible unless they meet the following criteria, a) participants who are off all immunosuppressive therapy, b) participants who have no signs and/or symptoms of acute or chronic graft versus host disease, or c) participants must have appropriate hematology counts~* Infection with human immunodeficiency virus (HIV), hepatitis B, or hepatitis C~* Uncontrolled autoimmune hemolytic anemia or thrombocytopenia~* Investigational or anti-cancer therapy within 5 half-lives prior to the first dose of study drug~* History of significant renal, neurologic, psychiatric, endocrinologic, metabolic, immunologic, cardiovascular, or hepatic disease

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: None
- Healthy Volunteers: f

Study Arms:
- Dose-Finding: Schedule A: Relapsed/Refractory CLL (Type: EXPERIMENTAL): All 4 cohorts will begin venetoclax administration after the ramp-up period of 5 weeks. In 4 cohorts of participants with relapsed/refractory CLL escalating doses of venetoclax will be administered in combination with fixed dose obinutuzumab in the dose-finding stage. In Schedule A, venetoclax will be introduced before obinutuzumab. Schedule A will be explored prior to Schedule B.
- Dose-Finding: Schedule B: Relapsed/Refractory CLL (Type: EXPERIMENTAL): In 4 cohorts of participants with relapsed/refractory CLL escalating doses of venetoclax will be administered in combination with fixed dose obinutuzumab in the dose-finding stage. In Schedule B, venetoclax will be introduced after obinutuzumab. Schedule A will be explored prior to Schedule B.
- Dose-Finding: Schedule A: Previously Untreated CLL (Type: EXPERIMENTAL): All 4 cohorts will begin venetoclax administration after the ramp-up period of 5 weeks. In 4 cohorts of participants with previously untreated CLL escalating doses of venetoclax will be administered in combination with fixed dose obinutuzumab in the dose-finding stage. In Schedule A, venetoclax will be introduced before obinutuzumab. Schedule A will be explored prior to Schedule B.
- Dose-Finding: Schedule B: Previously Untreated CLL (Type: EXPERIMENTAL): In 4 cohorts of participants with previously untreated CLL escalating doses of venetoclax will be administered in combination with fixed dose obinutuzumab in the dose-finding stage. In Schedule B, venetoclax will be introduced after obinutuzumab. Schedule A will be explored prior to Schedule B.
- Safety Expansion: Relapsed/Refractory CLL (Type: EXPERIMENTAL): In participants with relapsed/refractory CLL a recommended dose of venetoclax will be administered in combination with obinutuzumab in the safety expansion stage. Schedule A or B will be used for the expansion cohort after a review of available safety data from the dose finding stage.
- Safety Expansion: Previously Untreated CLL (Type: EXPERIMENTAL): In participants with previously untreated CLL a recommended dose of venetoclax will be administered in combination with obinutuzumab in the safety expansion stage. Schedule A or B will be used for the expansion cohort after a review of available safety data from the dose finding stage.

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: complete